These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29370211)

  • 1. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
    Hayes AR; Brungs D; Pavlakis N
    PLoS One; 2018; 13(1):e0191455. PubMed ID: 29370211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for advanced prostate cancer.
    Macherey S; Monsef I; Jahn F; Jordan K; Yuen KK; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006250. PubMed ID: 29278410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates for advanced prostate cancer.
    Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
    Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
    Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.
    Menshawy A; Mattar O; Abdulkarim A; Kasem S; Nasreldin N; Menshawy E; Mohammed S; Abdel-Maboud M; Gadelkarim M; El Ashal GG; Elgebaly AS
    Support Care Cancer; 2018 Apr; 26(4):1029-1038. PubMed ID: 29387997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
    LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
    Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
    Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and prevention of bone complications from prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.
    Ng TL; Tu MM; Ibrahim MFK; Basulaiman B; McGee SF; Srikanthan A; Fernandes R; Vandermeer L; Stober C; Sienkiewicz M; Jeong A; Saunders D; Awan AA; Hutton B; Clemons MJ
    Support Care Cancer; 2021 Feb; 29(2):925-943. PubMed ID: 32535678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.
    Porta-Sales J; Garzón-Rodríguez C; Llorens-Torromé S; Brunelli C; Pigni A; Caraceni A
    Palliat Med; 2017 Jan; 31(1):5-25. PubMed ID: 27006430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
    Peddi P; Lopez-Olivo MA; Pratt GF; Suarez-Almazor ME
    Cancer Treat Rev; 2013 Feb; 39(1):97-104. PubMed ID: 22898302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.